Rezolute (RZLT) Stock Forecast & Price Target

Rezolute is attractive fundamentally because FDA’s recommendation for a pre-BLA meeting after reviewing sunRIZE data suggests a viable regulatory path for ersodetug in congenital hyperinsulinism, without requesting an additional trial at this stage. The company also has meaningful late-stage catalysts in tumor hyperinsulinism, where upLIFT has seven confirmed responders and an objective endpoint that reduces behavioral confounding, strengthening confidence in a positive readout. Despite no revenue and likely future financing needs, the opportunity is supported by durable glycemic-control signals across sunRIZE, the open-label extension, and broader program data, with valuation underpinned by a revised 2036 discounted risk-adjusted revenue estimate of $1.3B.

Rezolute is facing meaningful clinical and commercial risk because its studies may be halted by unforeseen safety or tolerability issues, which would directly undermine confidence in Ersodetug and the company’s broader rare-disease pipeline. Even if the asset advances, the company could still be displaced by newer, more efficacious products that enter the market and compete for share in refractory hypoglycemia and hyperinsulinism. With a single reportable segment and dependence on securing financing for additional studies or eventual commercialization, the investment case remains highly vulnerable to execution, funding, and competitive setbacks.